Occult macular dystrophy

Occult macular dystrophy (OMD), also known as Miyake disease, is a rare inherited retinal disorder characterized by progressive decline in central visual acuity despite a normal-appearing fundus (back of the eye) on standard clinical examination. The disease primarily affects the macula, the central part of the retina responsible for sharp, detailed vision. Because the fundus appears normal on ophthalmoscopy and fluorescein angiography, the condition can be difficult to diagnose and is often initially misdiagnosed or overlooked — hence the term 'occult.' The hallmark diagnostic finding is a reduced or absent focal macular electroretinogram (fmERG) response, while the full-field electroretinogram (ffERG) typically remains normal, indicating that the dysfunction is localized to the macular cone photoreceptors. Optical coherence tomography (OCT) may reveal subtle thinning or disruption of the photoreceptor layer in the foveal region. Patients typically present with bilateral, slowly progressive loss of central vision, often first noticed in childhood or young adulthood, though the age of onset can vary. Visual acuity may range from mildly to moderately reduced. Color vision abnormalities may also be present. Peripheral vision is generally preserved. The most commonly implicated gene is RP1L1 (retinitis pigmentosa 1-like 1), with mutations inherited in an autosomal dominant pattern, though autosomal recessive inheritance has also been reported in some families. Other genetic causes have been described, including mutations in the KCNV2 gene in rare cases. There is currently no specific treatment or cure for occult macular dystrophy. Management is supportive and includes regular ophthalmologic monitoring, low-vision aids, and genetic counseling for affected individuals and their families. Research into gene therapy and other molecular approaches for inherited retinal dystrophies is ongoing, but no targeted therapy is yet available for OMD specifically.

Data sourced from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Common questions about Occult macular dystrophy